Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.09 +0.78 (+0.38%)

Streaming Delayed Price Updated: 3:47 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

99 100 Next >

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

October 14, 2025

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

October 14, 2025

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

October 14, 2025

From Johnson & Johnson

Via Business Wire

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Why Did Protagonist Therapeutics Stock Soar Today? ↗

October 10, 2025

Via Stocktwits

Stock Market Today: S&P 500, Nasdaq Futures Tumble Ahead Of Big Bank Earnings—Goldman Sachs, JPMorgan, Citigroup In Focus ↗

October 14, 2025

U.S. stock futures declined on Tuesday following Monday’s reversal rally. Futures of major benchmark indices were lower.

Via Benzinga

Topics Stocks

Earnings Scheduled For October 14, 2025 ↗

October 14, 2025

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Via Stocktwits

Topics Government World Trade

Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday ↗

October 14, 2025

US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings.

Via Benzinga

Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing ↗

October 13, 2025

Via The Motley Fool

Topics Regulatory Compliance

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside ↗

October 13, 2025

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.

Via Benzinga

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Via Benzinga

Dividend Powerhouses: Should You Grab These 3 Before Earnings Drop?

October 13, 2025

As the Q3 2025 earnings season hits full stride, a critical question looms for income-focused investors: are "dividend powerhouses" still a safe haven, and should they be considered before their...

Via MarketMinute

Topics Bonds Earnings Economy

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

Via Benzinga

Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts

October 13, 2025

New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early...

Via MarketMinute

Topics Economy Government Stocks

A Peek at Johnson & Johnson's Future Earnings ↗

October 13, 2025

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: Fastenal, ASML, TSMC And More ↗

October 13, 2025

Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this week.

Via Benzinga

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Topics ETFs Government World Trade

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗

October 13, 2025

U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...

Via Chartmill

Topics Artificial Intelligence Government World Trade

Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal ↗

October 12, 2025

Via The Motley Fool

Topics Regulatory Compliance

US Government Shutdown Rattles Global Markets, Igniting Uncertainty and Fueling Losses on October 10, 2025

October 10, 2025

The ongoing U.S. federal government shutdown, now in its tenth day as of October 10, 2025, has sent significant tremors through global financial markets. The persistent congressional deadlock over...

Via MarketMinute

Topics Bonds Economy World Trade

Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota

October 10, 2025

From Johnson & Johnson

Via Business Wire

Market Turmoil: S&P 500 and Nasdaq Plunge Amidst Renewed Trade Tensions and AI Scrutiny

October 10, 2025

New York, NY – October 10, 2025 – U.S. equity markets experienced a dramatic downturn today, with both the S&P 500 and Nasdaq Composite indices recording substantial losses, shattering a months-long...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗

October 10, 2025

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Via Benzinga

Is This Beaten-Down Dividend King a Buy? ↗

October 10, 2025

This company's short life on the stock market has been a constant challenge.

Via The Motley Fool

Topics Intellectual Property

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

October 10, 2025

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Government Shutdown Casts a Shadow: Economic Data Halted, Federal Reserve Navigates Blind

October 09, 2025

The ongoing government shutdown has plunged financial markets into a state of heightened uncertainty, as the vital flow of economic data—the lifeblood of informed decision-making—grinds to a halt. With...

Via MarketMinute

Topics Bonds Credit Cards Economy

Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Economy Intellectual Property Retirement

Dow Jones Takes a Tumble Amidst Government Shutdown Fears and Economic Headwinds

October 09, 2025

The Dow Jones Industrial Average (DJIA) experienced a notable slide today, October 9, 2025, as a confluence of a U.S. government shutdown, mounting economic concerns, and specific corporate...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.